From: Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Comorbidity/tumor characteristics | EBRT alone (%)* | EBRT+HT (%)* | EBRT+BT (%)* | EBRT+BT+HT (%)* | BT alone (%)* | BT+HT (%)* | RT (Type unknown)±HT (%)* |
---|---|---|---|---|---|---|---|
Total | 24.5 | 30.4 | 10.5 | 7.1 | 17.9 | 8.2 | 1.4 |
Piccirillo comorbidity score (nw = 8718, p = 0.5183)† | |||||||
None | 28.5 | 26.6 | 31.0 | 24.6 | 33.9 | 26.7 | 35.3 |
Mild | 54.4 | 54.9 | 55.0 | 60.2 | 52.9 | 60.9 | 49.3 |
Moderate | 12.9 | 14.8 | 10.5 | 10.6 | 10.1 | 9.1 | 9.6 |
Severe | 4.2 | 3.7 | 3.5 | 4.6 | 3.1 | 3.3 | 5.8 |
PSA (ng/ml) (nw = 8822, p < 0.0001)† | |||||||
<10 | 76.3 | 52.2 | 83.0 | 60.9 | 92.7 | 86.3 | 59.0 |
10–20 | 20.5 | 25.7 | 13.6 | 25.8 | 5.9 | 10.1 | 27.0 |
>20 | 3.2 | 22.1 | 3.4 | 13.3 | 1.4 | 3.6 | 14.0 |
Clinical T stage (nw = 8941, p < 0.0001)† | |||||||
Tx-T0 | 0.8 | 0.9 | 0.0 | 0.3 | 0.1 | 0.4 | 0.9 |
T1 | 70.5 | 53.0 | 66.3 | 49.4 | 77.0 | 79.2 | 46.7 |
T2 | 27.4 | 39.2 | 32.4 | 45.5 | 22.9 | 20.4 | 44.1 |
T3-T4 | 1.3 | 6.9 | 1.3 | 4.8 | 0.0 | 0.0 | 8.3 |
Gleason score (nw = 8879, p < 0.0001)† | |||||||
2–6 | 66.7 | 32.3 | 56.4 | 32.6 | 84.6 | 76.7 | 55.1 |
7 | 29.5 | 42.2 | 38.0 | 46.0 | 14.0 | 20.7 | 27.9 |
8–10 | 3.8 | 25.5 | 5.6 | 21.4 | 1.4 | 2.6 | 17.0 |
Recurrence risk group (nw = 8946, p < 0.0001)† | |||||||
LR | 46.7 | 16.5 | 43.9 | 15.0 | 75.4 | 62.7 | 31.2 |
IR | 46.1 | 41.8 | 47.3 | 56.7 | 21.8 | 31.4 | 38.8 |
HR | 7.2 | 41.7 | 8.8 | 28.3 | 2.8 | 5.9 | 30.0 |